Lessons learnt from 20 years surveillance of malaria drug resistance prior to the policy change in Burkina Faso.
The history of drug resistance to the previous antimalarial drugs, and the potential for resistance to evolve to Artemisinin-based combination therapies, demonstrates the necessity to set-up a good surveillance system in order to provide early warning of the development of resistance. Here we report a review summarizing the history of the surveillance of drug resistance that led to the policy change in Burkina Faso. The first Plasmodium falciparum Chloroquine-Resistance strain identified in Burkina Faso was detected by an in vitro test carried out in Koudougou in 1983. Nevertheless, no further cases were reported until 1987, suggesting that resistant strains had been circulating at a low prevalence before the beginning of the systematic surveillance system from 1984. We observed a marked increase of Chloroquine-Resistance in 2002-2003 probably due to the length of follow-up as the follow-up duration was 7 or 14 days before 2002 and 28 days from 2002 onwards. Therefore, pre-2002 studies have probably under-estimated the real prevalence of Chloroquine-Resistance by not detecting the late recrudescence. With a rate of 8.2% treatment failure reported in 2003, Sulfadoxine-Pyrimethamine was still efficacious for the treatment of uncomplicated malaria in Burkina Faso but this rate might rapidly increase as the result of its spreading from neighboring countries and due to its current use for both the Intermittent Preventive Treatment in pregnant women and Seasonal Malaria Chemoprophylaxis. The current strategy for the surveillance of the Artemisinin-based combination treatments resistance should build on lessons learnt under the previous period of 20 years surveillance of Chloroquine and Sulfadoxine-Pyrimethamine resistance (1994-2004). The most important aspect being to extend the number of sentinel sites so that data would be less patchy and could help understanding the dynamic of the resistance.
Institut de Recherche en Sciences de la Santé - Unité de Recherche Clinique de Nanoro (IRSS-URCN), Nanoro, Burkina Faso.|Centre Muraz, Bobo-Dioulasso, Burkina Faso.
Halidou
H
Tinto
Institut de Recherche en Sciences de la Santé - Unité de Recherche Clinique de Nanoro (IRSS-URCN), Nanoro, Burkina Faso.|Centre Muraz, Bobo-Dioulasso, Burkina Faso.
Innocent
I
Valea
Institut de Recherche en Sciences de la Santé - Unité de Recherche Clinique de Nanoro (IRSS-URCN), Nanoro, Burkina Faso.
Jean-Bosco
JB
Ouédraogo
Centre Muraz, Bobo-Dioulasso, Burkina Faso.
Tinga Robert
TR
Guiguemdé
D000962:Antimalarials / Q000494:pharmacology*; D002050:Burkina Faso / Q000453:epidemiology; D004351:Drug Resistance; D006291:Health Policy; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology / Q000469:parasitology*; D010963:Plasmodium falciparum / Q000187:drug effects*
D000962:Antimalarials